MDNA Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$36,712.50
Insider Selling (Last 12 Months): C$0.00

Medicenna Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Medicenna Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medicenna Therapeutics Share Price & Price History

Current Price: C$0.77
Price Change: Price Increase of +0.01 (1.32%)
As of 12/5/2022 03:36 PM ET

This chart shows the closing price history over time for MDNA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Medicenna Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2022Albert George BeraldoDirectorBuy25,000C$1.18C$29,482.50325,000
10/6/2022Albert George BeraldoDirectorBuy5,600C$1.15C$6,440.00295,300
9/29/2022Chandra PanchalDirectorBuy1,000C$0.79C$790.003,000
11/1/2021Elizabeth WilliamsSenior OfficerBuy4,000C$2.75C$10,982.8010,300
See Full Table

SEC Filings (Institutional Ownership Changes) for Medicenna Therapeutics (TSE:MDNA)

Medicenna Therapeutics logo
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Read More on Medicenna Therapeutics

Today's Range

Now: C$0.77
Low: C$0.72
High: C$0.77

50 Day Range

MA: C$0.93
Low: C$0.56
High: C$1.21

52 Week Range

Now: C$0.77
Low: C$0.55
High: C$2.49


21,315 shs

Average Volume

44,735 shs

Market Capitalization

C$53.62 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Medicenna Therapeutics?

Medicenna Therapeutics' top insider investors include:
  1. Albert George Beraldo (Director)
  2. Elizabeth Williams (Senior Officer)
  3. Chandra Panchal (Director)
Learn More about top insider investors at Medicenna Therapeutics.